Kidney Transplant Rejection Market Expansion Is Opening New Pathways For Strategic Investment
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Kidney Transplant Rejection Market CAGR Analysis And Future Market Development
The kidney transplant rejection market size has experienced substantial expansion in recent times. It is projected to increase from $3.51 billion in 2025 to $3.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. This historical expansion can be attributed to several factors: a rise in kidney transplant procedures, progress in histopathological assessment techniques, broader access to immunosuppressive drugs, the proliferation of transplant center networks, and enhanced post-transplant patient survival rates.
The kidney transplant rejection market size is anticipated to experience robust expansion over the next few years. It is projected to increase to $5.01 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.4%. The expected growth during this forecast period can be attributed to an escalating demand for personalized immunosuppression strategies, the increasing adoption of molecular diagnostics, the broadening scope of precision medicine in transplant care, a heightened focus on long-term graft survival, and growing investments in transplant monitoring technologies. Notable trends within the forecast period include the expanding use of biomarker-based rejection monitoring, the rising application of genomics-based diagnostic approaches, ongoing optimization of immunosuppressive therapy protocols, the proliferation of non-invasive rejection surveillance methods, and an intensified focus on the early detection of chronic rejection.
Download A Free Sample Report For Comprehensive Market Insights:
Kidney Transplant Rejection Market Expansion Drivers: What Is Shaping Future Growth?
The increasing occurrence of end-stage renal disease is projected to fuel the expansion of the kidney transplant rejection market in the future. End-stage renal disease (ESRD) is defined as the last, irreversible phase of chronic kidney disease where kidneys are unable to perform their functions sufficiently without interventions like dialysis or a kidney transplant. The occurrence of end-stage renal disease is growing because of the widespread increase in chronic conditions such as diabetes and hypertension, which gradually impair kidney function, resulting in kidney failure. Kidney transplant rejection necessitates sophisticated monitoring and treatment strategies, thereby directly aiding in managing end-stage renal disease by helping transplanted kidneys stay viable and patients preserve their renal health. For example, as reported in September 2024 by the National Institute of Diabetes and Digestive and Kidney Diseases, a US-based government institute, over 808,000 individuals in the United States were living with end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD), in 2023, with 68% undergoing dialysis and 32% having received a kidney transplant. Consequently, the increasing prevalence of end-stage renal disease is propelling the expansion of the kidney transplant rejection market.
Kidney Transplant Rejection Market Segments: Where Are The Largest Growth Opportunities?
The kidney transplant rejection market covered in this report is segmented –
1) By Rejection Type: Chronic Rejection; Acute Rejection
2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies
3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics
4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies
5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies
Subsegments:
1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection
2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection
Kidney Transplant Rejection Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Companies operating within the kidney transplant rejection market are prioritizing the creation of advanced diagnostic solutions, such as noninvasive urinary biomarker testing, to facilitate more rapid, secure, and precise detection of transplant rejection. This noninvasive urinary biomarker testing method involves analyzing urine samples to identify molecular indicators of kidney inflammation or rejection, thereby assisting clinicians in quickly and safely pinpointing transplant complications without requiring invasive biopsies. For instance, in May 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, introduced the CXCL10 testing service, an innovative diagnostic tool specifically for kidney transplant recipients. The CXCL10 test detects the CXCL10 chemokine in urine, which is associated with early transplant rejection and inflammation. It delivers results within 24 hours, allowing for quicker clinical decisions, reducing the need for unnecessary biopsies, and enhancing patient convenience by utilizing noninvasive sample collection. Developed and validated by Thermo Fisher’s One Lambda Laboratories, this assay merges high sensitivity and specificity with practical ease of use in clinical settings, ultimately supporting improved post-transplant care and patient outcomes.
Kidney Transplant Rejection Market Major Participants And Competitive Dynamics
Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.
Access The Complete Kidney Transplant Rejection Market Report:
Kidney Transplant Rejection Market Largest Region By Revenue And Market Share
North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
